⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 30, 1997New England Journal of Medicine

Should Thrombolytic Therapy Be the First-Line Treatment for Acute Ischemic Stroke?

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does intravenous recombinant tissue plasminogen activator (t-PA) improve outcomes in patients with acute ischemic stroke?

Population

Patients with acute ischemic stroke

Design

Editorial

Authors

LCL R CaplanTufts Medical Center JMJ P Mohr JKJ P Kistler

Discussion

Loading...

Member takes

Implication

This editorial discusses the role and limitations of thrombolytic therapy as a first-line treatment for acute ischemic stroke.

Structured PICO

Does intravenous recombinant tissue plasminogen activator (t-PA) improve outcomes in patients with acute ischemic stroke?

P

Population

Patients with acute ischemic stroke

I

Intervention

Intravenous recombinant tissue plasminogen activator (t-PA)

This editorial discusses the role and limitations of thrombolytic therapy as a first-line treatment for acute ischemic stroke.

Cite This Study

Caplan et al. (1997) studied this question.

synapsesocial.com/papers/6a6fe6dc75498292b70946d6 https://doi.org/10.1056/nejm199710303371812

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Tissue Plasminogen Activator for Acute Ischemic Stroke1995 · 11,765 citations
2Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.1993 · 183 citations
3Thrombolysis and Stroke1987 · 133 citations
4Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.1992 · 350 citations
5Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke1992 · 1,005 citations